Generate Biomedicines, Inc. (GENB)
NASDAQ: GENB · Real-Time Price · USD
16.47
+0.05 (0.30%)
At close: Jun 26, 2026, 4:00 PM EDT
16.95
+0.48 (2.90%)
After-hours: Jun 26, 2026, 7:41 PM EDT
Generate Biomedicines Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Generate Biomedicines stock have an average target of 25.4, with a low estimate of 22 and a high estimate of 30. The average target predicts an increase of 54.22% from the current stock price of 16.47.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Generate Biomedicines stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|
| Strong Buy | 3 | 4 | 4 |
| Buy | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Buy Reiterates $30 | Buy | Reiterates | $30 | +82.15% | Jun 25, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $20 → $22 | Buy | Maintains | $20 → $22 | +33.58% | May 14, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $24 | Buy | Reiterates | $24 | +45.72% | May 8, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $25 | Buy | Reiterates | $25 | +51.79% | May 8, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Maintains $26 | Buy | Maintains | $26 | +57.86% | Apr 10, 2026 |
Financial Forecast
Revenue This Year
25.89M
from 31.89M
Decreased by -18.81%
Revenue Next Year
23.67M
from 25.89M
Decreased by -8.60%
EPS This Year
-2.24
EPS Next Year
-2.07
from -2.24
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 37.2M | 40.0M | |
| Avg | 25.9M | 23.7M | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 16.6% | 54.5% | |
| Avg | -18.8% | -8.6% | |
| Low | -100.0% | -100.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | -2.24 | -2.07 | |
| Low | - | - |
EPS Growth
| EPS Growth | 2027 | 2028 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.